A5020198609- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Luminescence and Fluorescent Materials
- CAR-T cell therapy research
- Nicotinic Acetylcholine Receptors Study
- Sepsis Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Photoreceptor and optogenetics research
- Neuroscience and Neural Engineering
- Ion channel regulation and function
- Nanoplatforms for cancer theranostics
- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Molecular Communication and Nanonetworks
- Long-Term Effects of COVID-19
- Polydiacetylene-based materials and applications
- Neuroscience of respiration and sleep
- Diet and metabolism studies
Baylor College of Medicine
2024
The University of Texas at Austin
2022-2024
The University of Texas Medical Branch at Galveston
2020
Optogenetics has revolutionized neuroscience understanding by allowing spatiotemporal control over cell-type specific neurons in neural circuits. However, the sluggish development of noninvasive photon delivery brain limited clinical application optogenetics. Focused ultrasound (FUS)-derived mechanoluminescence emerged as a promising tool for situ emission, but there is not yet biocompatible liquid-phase system To achieve optogenetics with high temporal resolution and desirable...
Background Dexamethasone was approved for use in hospitalized COVID-19 patients early the pandemic based on RECOVERY trial, but evidence is still needed to support its real-world effectiveness heterogeneous populations of with a wide range comorbidities. Methods inpatients represented within National COVID Cohort Collaborative (N3C) Data Enclave, prior vaccine availability, were studied. Primary outcome in-hospital death; secondary combined death and severe defined by ECMO or mechanical...
The voltage-gated Na+ (Nav) channel is the molecular determinant of excitability. Disruption protein–protein interactions (PPIs) between Nav1.6 and fibroblast growth factor 14 (FGF14) leads to impaired excitability neurons in clinically relevant brain areas associated with channelopathies. Here, we designed, synthesized, pharmacologically characterized new peptidomimetics based on a PLEV tetrapeptide scaffold derived from FGF14:Nav1.6 PPI interface. Addition an N-terminal...
To develop a regulatory T cell (Treg)-based therapy for the treatment of progressive multiple sclerosis (MS).
ABSTRACT Background Dexamethasone, a widely available glucocorticoid, was approved for use in hospitalized COVID-19 patients early the pandemic based on RECOVERY trial; however, evidence is still needed to support its real-world effectiveness with wide range of comorbidities and diverse care settings. Objectives To conduct comparative analysis dexamethasone without remdesivir using electronic health record data. Methods We conducted retrospective harmonized, highly granular data National...